Indian semaglutide brands became a major product-identification topic in 2026 as multiple companies announced injections for diabetes or weight management. Names such as Obeda, Noveltreat, Sematrinity, Semaglyn, Semanext, Semasize and GLIPIQ can refer to different companies, devices or labeled indications. A reliable comparison begins with documentary evidence of the company, product presentation and Indian regulatory context, not an online seller’s assertion that all are generic Ozempic.
This directory is for readers researching those brands from the United States. An authorization by India’s drug regulator, the DCGI operating through the CDSCO framework, does not constitute U.S. FDA approval. The FDA-approved U.S. product directory is the right starting point for products legally approved in the United States; the imported semaglutide guide explains why cross-border offers require a separate regulatory check.
The table below records what announced manufacturer materials actually identify, including co-marketing arrangements where one Zydus formulation carries multiple brand names. It is not a seller directory, product ranking, import service or current stock report. No products or companies here are presented as substitutes for a U.S. prescription, and similarities in active ingredient or injection format do not establish FDA-approved therapeutic interchangeability.
On March 21, 2026, Dr. Reddy’s announced Obeda for type 2 diabetes, Sun Pharma confirmed both Noveltreat and Sematrinity, Alkem introduced Semasize alongside other trade names, and Glenmark announced GLIPIQ. Their press materials provide clearer evidence about product identity than retailer listings, advertising or social posts. The companies did not all release the same administration device or the same India-labeled indication.
The timing of a commercial announcement is not by itself a confirmation of continuing product availability, every listed strength, a manufacturing site or approvals outside India. Treat source dates as part of the product facts, and seek current packaging information from legitimate Indian professional channels where the reader is researching the Indian market.
Sun Pharma’s January and March announcements distinguish Noveltreat, a weight-management brand, from Sematrinity, its diabetes-oriented brand. Dr. Reddy’s launch described Obeda for type 2 diabetes. Glenmark marketed GLIPIQ for diabetes; Alkem described approval covering diabetes and chronic weight management in its company announcement. A directory that collapses these into “Ozempic alternatives” ignores material local labeling distinctions.
A product’s Indian clinical indication cannot be copied onto U.S. FDA labeling for Ozempic, Wegovy or other brands. The Ozempic guide and Wegovy guide cover U.S.-approved product families, whose formulations and indications are individually established. No India-listed pen should be assigned a U.S. indication merely because it contains semaglutide.
Zydus announced a 15 mg/3 mL semaglutide cartridge intended for administration with a reusable pen. In its March 17 deal, Lupin received rights to market the related product under Semanext and Livarise; Zydus retained brands including Semaglyn, Mashema and Alterme. A March 18 agreement gave Torrent the right to market the Zydus-supplied product as Sembolic.
This is a critical manufacturer-versus-marketer distinction. Multiple brand names in that network do not constitute proof of multiple independent formulations or different efficacy. Read Semaglyn, Semanext and the manufacturer relationship guide before interpreting company names on a listing.
Obeda was announced in disposable pre-filled pens with 2 mg and 4 mg total-strength presentations. Sun discussed prefilled injectable products, while Glenmark’s GLIPIQ includes both a vial used with dose-specific syringes and a prefilled pen. Zydus described a replaceable cartridge used in a reusable pen. Alkem separately noted disposable pens and reusable devices for some presentations.
Device architecture matters for product identification, labeling, storage, supply packages and professional training. The total drug content in a cartridge is not the amount given at each administration, and a U.S. approved pen cannot be replaced with a foreign product on the strength of a superficial appearance match. No cross-device dosing instructions or conversion chart is appropriate here.
The strongest starting point is an India regulator document or a dated company filing specifying the brand, formulation, approved local use and applicable marketing status. A company press release can substantiate its own announced launch or distribution arrangement; it does not necessarily disclose the complete marketing authorization, all packs, every contract manufacturer or post-launch inventory.
Third-party catalogs can be useful search leads but may conflate brands, claim unverified variants or attribute products to a marketer as if it manufactured them. The corresponding manufacturer map records separately who developed, supplied and marketed each named product, and marks unknown fields as unverified rather than filling gaps.
U.S. generic-drug status is established through an applicable FDA approval, not an Indian brand launch or patent event. Brand identity, ingredient name and a local efficacy trial do not by themselves make an imported product FDA-approved, pharmacy-eligible or interchangeable with an American brand. A U.S. buyer should not use these names as shopping links.
FDA enforcement against an American online seller offering the Indian brand Semanat illustrates the distinction between an overseas marketed product and an unapproved U.S. offer; it does not imply wrongdoing by every Indian manufacturer. For the buyer question, see generic semaglutide verification and compounding rules.
We retain one page per brand when its product, manufacturer, indication or delivery device gives readers a genuinely separate reason to search. Obeda is a Dr. Reddy’s product, Noveltreat and Sematrinity are different Sun Pharma indications, GLIPIQ presents vial/pen differences, and Semaglyn versus Semanext separates platform origin from a licensed marketer.
Sister trade names such as Alkem’s Obesema and Hepaglide, or Zydus’ Mashema and Alterme, are covered inside their primary family pages until there is enough distinct documentation to justify standalone content. This prevents near-identical affiliate-style pages that add no new buyer insight.
Start with the exact printed trade name and manufacturer or marketer, then identify the ingredient, concentration, dosage form, device, approved local indication and the date of the document supporting those details. Check whether the name belongs to a shared licensing agreement before assuming a separate manufacturer. Unverified strengths, current pricing and retailer inventory should be left blank.
If the purpose is treatment in the U.S., switch to the U.S. prescription and pharmacy guide rather than contacting offshore sellers. A site suggesting imported non-FDA-approved pens as direct replacements is not solving the regulatory or safety question, even if it advertises lower prices.
India launch stories often emphasize affordability, but prices printed in separate announcements refer to different presentations, calendar dates and commercial channels. Comparing a vial, reusable cartridge and prefilled disposable pen using headline weekly prices without normalizing the actual labeled pack would create a misleading ranking.
This hub therefore omits live-style price tables and purchase buttons. The primary task is determining whether a brand is documented, what company is responsible and whether local regulatory authorization can actually be substantiated. For U.S. patients, the only sensible buying route is a valid prescription and FDA-approved product from a licensed pharmacy.
Read each row as a brand-identity record for the Indian market. Compare the named marketer, documented development or supply arrangement, local indication and device: a Zydus cartridge associated with a partner brand is not the same identification question as GLIPIQ supplied in vial and pen presentations.
For any name not yet documented in a regulator record or company release, mark the ingredient, device or marketing partner as unverified rather than inferring it from neighboring brands. A press release about an India launch does not show that a specific strength is currently stocked or that the product has a U.S. FDA application.
| Indian brand | Company or marketer | Documented product angle | In-depth page |
|---|---|---|---|
| Obeda | Dr. Reddy’s | Diabetes; disposable pen | Identify Obeda |
| Noveltreat | Sun Pharma | Weight management; prefilled injection | Review Noveltreat |
| Sematrinity | Sun Pharma | Type 2 diabetes; injection | Review Sematrinity |
| Semaglyn / Semanext | Zydus platform / Lupin co-marketing | Reusable pen with 15 mg/3 mL cartridge | Platform identity |
| Semasize | Alkem | India injectable family; sister trade names | Alkem family |
| GLIPIQ | Glenmark | Diabetes; vial and pen | Device details |
This directory identifies Indian semaglutide trade names for research, not U.S. purchase. It does not sell, import or dispense Obeda, Noveltreat, Sematrinity, Semaglyn, Semanext, Semasize or GLIPIQ. The reader-facing test is whether each claimed brand, indication and form can be traced to a dated Indian approval or first-party disclosure. Where an item cannot be confirmed, it should not become an implied recommendation.
Brand and indication descriptions were reviewed using Indian company announcements and the U.S. FDA approval framework as of October 18, 2026. The listed products do not become FDA-approved Ozempic or Wegovy generics merely because they contain semaglutide. Commercial referrals elsewhere on this website may earn compensation where identified, but this page provides no foreign-pharmacy sales route.
Indian approval is not U.S. FDA approval. Each U.S. product requires its own applicable FDA authorization.
Both names relate to semaglutide, but they are distinct branded products in different regulatory markets. Shared ingredient does not prove interchangeability.
Its March 2026 materials distinguish Noveltreat for weight management from Sematrinity for type 2 diabetes in India.
The March 2026 Lupin–Zydus agreement identifies a Zydus-developed and supplied formulation that Lupin co-markets under Semanext.
No. The stated figure describes total concentration or cartridge content, not a patient-specific administration amount.
No. Dated launch announcements do not establish current inventory, retail pricing or seller legitimacy.
Several names share the same company or product platform; consolidating them avoids repeating the same facts without meaningful new information.
This directory does not provide purchasing routes for foreign products lacking applicable U.S. approval.
Check the specific FDA-approved application and product listing, then verify the dispensing pharmacy and the prescribed product rather than relying on an Indian approval claim.